摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2-氧代-2,3,4,5-四氢-1H-苯并b氮杂革-3-基)-氨基甲酸叔丁酯 | 86499-69-6

中文名称
(2-氧代-2,3,4,5-四氢-1H-苯并b氮杂革-3-基)-氨基甲酸叔丁酯
中文别名
——
英文名称
tert-butyl (2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)carbamate
英文别名
1,1-dimethylethyl (2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl)carbamate;tert-butyl N-(2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)carbamate;tert-butyl N-(2-oxo-1,3,4,5-tetrahydro-1-benzazepin-3-yl)carbamate
(2-氧代-2,3,4,5-四氢-1H-苯并b氮杂革-3-基)-氨基甲酸叔丁酯化学式
CAS
86499-69-6
化学式
C15H20N2O3
mdl
——
分子量
276.335
InChiKey
KMQMLZIXVMSMOI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    472.5±44.0 °C(Predicted)
  • 密度:
    1.17±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    67.4
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090

SDS

SDS:1972a02d99b1138406f0f4ed2dad3b06
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
    申请人:Ciba-Geigy Corporation
    公开号:US04575503A1
    公开(公告)日:1986-03-11
    Variously substituted 1-carboxymethyl-3-(carboxymethylamino)-2,3,4,5-tetrahydro-1H-[1]benzazepin -2-ones and functional derivatives are angiotensin converting enzyme inhibitors and are useful as antihypertensive agents. Synthesis of, compositions and methods of treatment utilizing such compounds are included.
    取代基不同的1-羧甲基-3-(羧甲基基)-2,3,4,5-四氢-1H-[1]苯并氮杂䓬-2-酮及其功能性衍生物血管紧张素转化酶抑制剂,并可作为抗高血压药使用。包括这些化合物的合成、组合物及治疗方法。
  • AZEPINONE DERIVATIVES
    申请人:Okamoto Osamu
    公开号:US20110212891A1
    公开(公告)日:2011-09-01
    The present invention relates to a compound represented by formula (I): wherein R 1 represents a hydrogen atom or the like; R 2 and R 3 represent a hydrogen atom or the like; R 4 is a group represented by (II) R 5 represents a phenyl group which may be substituted with a halogen or the like; m is an integer of from 1 to 3; and p is an integer of from 0 to 4; or a pharmaceutically acceptable salt thereof.
    本发明涉及一种由以下式(I)表示的化合物:其中R1代表氢原子或类似物;R2和R3代表氢原子或类似物;R4是由(II)表示的基团;R5代表可能被卤素或类似物取代的苯基;m为1至3的整数;p为0至4的整数;或其药学上可接受的盐。
  • Lactam inhibitors of factor Xa and method
    申请人:——
    公开号:US20020025957A1
    公开(公告)日:2002-02-28
    Lactam inhibitors are provided which have the structure 1 including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrug esters thereof, wherein n is 1 to 5; and and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 10a , 10 11 and R 12 are as defined herein. These compounds are inhibitors of Factor Xa and thus are useful as anticoagulants. A method for treating cardiovascular diseases associated with thromboses is also provided.
    提供了具有以下结构的内酰胺抑制剂 1 ,包括其药用可接受的盐及其所有立体异构体,以及其前药酯,其中n为1至5;和 和R 1 ,R 2 ,R 3 ,R 4 ,R 5 ,R 6 ,R 7 ,R 8 ,R 9 ,R 10 ,R 10a ,10 11 和R 12 如本文所定义。这些化合物是因子Xa的抑制剂,因此可用作抗凝剂。还提供了一种用于治疗与血栓相关的心血管疾病的方法。
  • [EN] BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE<br/>[FR] COMPOSÉS DE CARBAMOYLPYRIDONE TRICYCLIQUE PONTÉS ET LEUR UTILISATION PHARMACEUTIQUE
    申请人:GILEAD SCIENCES INC
    公开号:WO2020197991A1
    公开(公告)日:2020-10-01
    Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    本发明揭示了用于治疗或预防人类免疫缺陷病毒(HIV)感染的化合物。这些化合物具有以下式(I):包括立体异构体和其药用可接受的盐,其中R1、R2、L、W1、W2、X、Y和Z如本文所定义。本发明还揭示了与这些化合物的制备和使用相关的方法,以及包含这些化合物的药物组合物。
  • Thrombin inhibitors having a lactam at P3
    申请人:Corvas International, Inc.
    公开号:US06541467B1
    公开(公告)日:2003-04-01
    The present invention provides compounds having a lactam ring at P3 and at P1 have a six-membered heterocyclic ring having two ring nitrogen ring atoms and the remainder of the ring atoms carbon atoms. These compounds have biological activity as active and potent inhibitors of thrombin. Their pharmaceutically acceptable salts, pharmaceutical compositions thereof and methods of using these compounds and pharmaceutical compositions comprising these compounds as therapeutic agents for treatment of disease states in mammals which are characterized by abnormal thrombosis are also described.
    本发明提供了化合物,其在P3处具有内酰胺环,在P1处具有一个六元杂环,其中有两个环氮原子和其余环原子为碳原子。这些化合物具有生物活性,作为凝血酶的活性和有效的抑制剂。还描述了这些化合物的药学上可接受的盐,其制剂以及使用这些化合物和包含这些化合物的制剂作为治疗哺乳动物中的疾病状态的治疗剂的方法。这些疾病状态以异常血栓形成为特征。
查看更多